Home LiteratureArticle Details
PMID: 8408541 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Construction of a bioluminescent mycobacterium and its use for assay of antimycobacterial agents.

Journal of clinical microbiology ·Vol. 31 ·No. 9 ·1993-09-00 ·Pages 2251-4

Andrew PW, Roberts IS

Abstract

To show, as a model system, that mycobacteria can express heterologous luciferase genes and that bioluminescence can be a rapid method of measuring antimycobacterial activity, a bioluminescent form of Mycobacterium smegmatis was made by transformation with a Mycobacterium-Escherichia coli shuttle vector containing the luxAB genes from Vibrio harveyi. The antimycobacterial effects of antibiotics and biocides could be assayed in real time by using bioluminescent M. smegmatis.

MeSH Terms
Anti-Bacterial Agents/pharmacology Luciferases/genetics Luminescent Measurements Microbial Sensitivity Tests Mycobacterium/drug effects,genetics
Chemicals
Anti-Bacterial Agents Luciferases
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Andrew P W
Department of Microbiology, University of Leicester, United Kingdom.
Roberts I S
References (13)
13 references, click to expand
  1. Microbiological applications of the inactivation of antibiotics and other antimicrobial agents.
    J Appl Bacteriol. 1979 Apr;46(2):207-45 PMID: 378921
  2. Disinfection of the flexible fibreoptic bronchoscope against Mycobacterium tuberculosis and M gordonae.
    Thorax. 1984 Oct;39(10):785-8 PMID: 6437002
  3. Kinetics of the tuberculocidal response by alkaline glutaraldehyde in solution and on an inert surface.
    J Appl Bacteriol. 1986 Jul;61(1):87-93 PMID: 3093441
  4. Effects of recombinant interferon-gamma and chemotherapy with isoniazid and rifampicin on infections of mouse peritoneal macrophages with Listeria monocytogenes and Mycobacterium microti in vitro.
    Br J Exp Pathol. 1986 Oct;67(5):707-17 PMID: 3098272
  5. In vitro observations on the suitability of new rifamycins for the intermittent chemotherapy of tuberculosis.
    Tubercle. 1987 Sep;68(3):183-93 PMID: 2834843
  6. Tuberculosis and human immunodeficiency virus infection.
    J Infect Dis. 1989 Jan;159(1):96-100 PMID: 2642524
  7. Drug resistant tuberculosis.
    BMJ. 1992 Oct 3;305(6857):831-2 PMID: 1422378
  8. In vivo bioluminescence: new potentials for microbiology.
    Lett Appl Microbiol. 1990 Jan;10(1):1-8 PMID: 1366572
  9. Isolation and characterization of efficient plasmid transformation mutants of Mycobacterium smegmatis.
    Mol Microbiol. 1990 Nov;4(11):1911-9 PMID: 2082148
  10. PCR based gene engineering of the Vibrio harveyi lux operon and the Escherichia coli trp operon provides for biochemically functional native and fused gene products.
    Mol Gen Genet. 1991 Apr;226(1-2):41-8 PMID: 2034229
  11. New use of BCG for recombinant vaccines.
    Nature. 1991 Jun 6;351(6326):456-60 PMID: 1904554
  12. The global tuberculosis situation and the new control strategy of the World Health Organization.
    Tubercle. 1991 Mar;72(1):1-6 PMID: 1882440
  13. HIV infection and tuberculosis.
    BMJ. 1990 Jan 13;300(6717):63-5 PMID: 2105772
Article Info
Journal
Journal of clinical microbiology
Abbr.
J Clin Microbiol
ISSN
0095-1137
DOI
10.1128/jcm.31.9.2251-2254.1993
Published
1993-09-00
Pages
2251-4
Language
English
Region
United States
NLM ID
7505564
PMCID
PMC265743
Subset
IM
External Links
PubMed source DOI: 10.1128/jcm.31.9.2251-2254.1993 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2